640 EPIDERMAL GROWTH FACTOR GENETIC POLYMORPHISM PREDICTS RISK OF HEPATOCELLULAR CARCINOMA IN EGYPTIAN PATIENTS WITH HCV (GENOTYPE 4)-RELATED CIRRHOSIS

2013 ◽  
Vol 58 ◽  
pp. S261 ◽  
Author(s):  
M. El-Bendary ◽  
M. Neamatallah ◽  
M. Abd El-Maksoud ◽  
A. El-Gendy ◽  
A. El-Wehedy ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Genetic Polymorphism ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Egyptian Patients ◽  
Epidermal Growth

scholarly journals Genetic polymorphism of epidermal growth factor gene as a predictor of hepatocellular carcinoma in hepatitis C cirrhotic patients

2021 ◽  
Vol 34 (1) ◽  
pp. 112
Author(s):  
MohamedM. M. Elhoseeny ◽  
Ibrahim Baghdadi ◽  
KhaledA Abu Ella ◽  
Ahmed Elsharawy ◽  
Elsayed Elshayb ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Genetic Polymorphism ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Factor Gene ◽  
Growth Factor Gene ◽  
Epidermal Growth ◽  
Cirrhotic Patients

Interrupted crosstalk between natural killer cells and anti-epidermal growth factor receptor: a possible role in hepatocellular carcinoma treatment failure

2021 ◽  
Vol 21 ◽  
Author(s):  
Hadeer Abosalema ◽  
Shahenda Mahgoub ◽  
Mohamed Emara ◽  
Nahla Kotb ◽  
Sameh Soror
Keyword(s):  
Hepatocellular Carcinoma ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Major Health Problem ◽  
Advanced Stages ◽  
Epidermal Growth ◽  
First Time ◽  
Late Stages

: Hepatocellular carcinoma (HCC) is a major health problem worldwide. Most patients are diagnosed for the first time at late stages; this leads to a very poor prognosis. It is challenging to discover strategies for treatment at these advanced stages. Recently, monoclonal antibodies (mAbs) targeting specific cellular signaling pathways in HCC have been developed. Unfortunately, they still have a low survival rate, and some of them failed clinically to produce effective responses even if they showed very good results against HCC in preclinical studies. This review focuses on and discusses the possible causes for the failure of mAbs, precisely anti-Epidermal Growth Factor Receptor (EGFR) mAb and the crosstalk between this mAb and patients' NK cells.

Sign in / Sign up

Export Citation Format

Share Document